Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Investigation of Dysregulated Signaling in MPD Via Multiparameter Phospho-specific Flow Cytometry

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Stanford University
ClinicalTrials.gov Identifier:
NCT01144780
First received: June 14, 2010
Last updated: June 29, 2016
Last verified: June 2016
  Purpose
The objective of this study is to better understand the underlying pathogenetic mechanisms of MPDs. We will collect peripheral blood samples from MPD patients and utilize multiparameter phospho-specific flow cytometry to investigate dysregulated signaling in blood cells from these patients. This will provide deeper insights into the pathogenesis of MPDs and may lead to the identification of novel targets for therapeutic intervention.

Condition
Myeloproliferative Disorders
Myeloproliferative Disorders (MPD)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Investigation of Dysregulated Signaling in Myeloproliferative Disorders Via Multiparameter Phospho-specific Flow Cytometry

Resource links provided by NLM:


Further study details as provided by Stanford University:

Biospecimen Retention:   Samples Without DNA
blood and bone marrow

Enrollment: 10
Study Start Date: September 2009
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Any patient who carries a diagnosis of a myeloproliferative disorder (MPD).
Criteria

Inclusion Criteria:Any patient who carries a diagnosis of a myeloproliferative disorder (MPD).

Exclusion Criteria:Any patient who is not willing to give consent.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01144780

Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Jason Robert Gotlib Stanford University
Principal Investigator: Stephen Tracy Oh Stanford University
  More Information

Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT01144780     History of Changes
Other Study ID Numbers: HEMMPD0011  SU-07092009-3060 
Study First Received: June 14, 2010
Last Updated: June 29, 2016
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Disease
Myeloproliferative Disorders
Pathologic Processes
Bone Marrow Diseases
Hematologic Diseases

ClinicalTrials.gov processed this record on December 06, 2016